Catalog No.
Product Name
Application
Product Information
Citations
-
Proton pump inhibitor
Esomeprazole sodium is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
ATPase Inhibitors
Omeprazole is a cell-permeable, selective proton pump inhibitor. -
Proton Pump inhibitor
Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion. -
proton pump inhibitor
Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 uM. -
Proton pump inhibitor
Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. - M2 ion channel blocker is capable of inhibiting and blocking the activity of M2 ion channel. Antiviral agents.
-
proton pump inhibitor
Rabeprazole sodium is an antiulcer drug in the class of proton pump inhibitors. - Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
-
Proton pump inhibitor
Lauric acid is a proton pump inhibitor potentially for the treatment of helicobacter pylori infections. -
proton pump inhibitor
(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM. -
H(+)-K(+)-exchanging ATPase inhibitor
Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole sodium(AG-1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138. -
gastric H+/K+ ATPase inhibitor
Soraprazan is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase. -
Proton Pump inhibitor
Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. -
gastric H+/K+-ATPase inhibitor
Tegoprazan, a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. -
H+/K+-ATPase inhibitor
Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1??0.4 μM. -
Proton Pump Inhibitor
Revaprazan is a reversible proton pump inhibitor that targets gastric acid secretion. It provides protection to the gastric mucosa and inhibits the degradation of IkappaB-alpha, as well as the inactivation of Akt, leading to a reduction in H. pylori-induced COX-2 expression. This compound is valuable in research applications related to infection and inflammation, particularly in studies of H. pylori-infected gastric inflammation and gastric ulcer pathophysiology. -
Proton Pump Inhibitor
Pantoprazole sodium is a potent proton pump inhibitor that specifically targets the H+/K+-ATPase enzyme with an IC50 of 6.8 μM. This substituted benzimidazole effectively reduces gastric acid secretion, demonstrating significant anti-secretory and anti-ulcer activities. Additionally, studies indicate that Pantoprazole sodium can enhance tumor growth delay when used in combination with Doxorubicin, making it a valuable tool in cancer research and gastrointestinal studies. -
Antimicrobial Agent
Zinc Pyrithione is an antimicrobial agent primarily known for its antifungal and antibacterial properties, acting by disrupting membrane transport through the inhibition of proton pumps. Additionally, it functions as a copper ionophore, facilitating the delivery of copper ions into cells. This compound serves as a valuable tool in the study of cuproptosis, providing insights into copper metabolism and its implications in various biological processes. -
Proton Pump Inhibitor
Omeprazole sodium is a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion, making it useful in treating acid-related gastrointestinal disorders. In addition to its primary role, omeprazole sodium competitively inhibits CYP2C19 with a Ki value ranging from 2 to 6 μM, which may influence drug metabolism. This compound also displays antibacterial activity against both Gram-positive and Gram-negative bacteria, and it serves as a potent inhibitor of neutral sphingomyelinase (N-SMase), impacting exosome production. Its diverse biological activities make it a valuable tool for research in pharmacology and microbiology. -
Apoptosis Inducer
Rabeprazole-d4 is a deuterated derivative of Rabeprazole, primarily acting as an apoptosis inducer through its irreversible inhibition of gastric H+/K+-ATPase. This second-generation proton pump inhibitor also functions as a uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole-d4 is valuable for research focused on gastric ulcerations and gastroesophageal reflux diseases, facilitating studies on its mechanisms of action and therapeutic potential. -
Stable Isotope
Pantoprazole-d6 is a deuterated form of Pantoprazole, a potent proton pump inhibitor (PPI) targeting H+/K+-ATPase with an IC50 of 6.8 μM. This stable isotope is primarily utilized in pharmacokinetic studies and metabolic investigations. Pantoprazole exhibits significant anti-secretory and anti-ulcer activities, enhancing pH stability while demonstrating the potential to improve tumor growth delay when combined with Doxorubicin. -
PP Inhibitor
Pantoprazole sodium hydrate is a potent proton pump inhibitor (PPI) that targets the H+/K+-ATPase enzyme. With an IC50 value of 6.8 μM, it exhibits significant anti-secretory and anti-ulcer properties. This compound has been demonstrated to enhance tumor growth delay when used in combination with Doxorubicin, making it a valuable reagent for studies involving cancer treatment and gastrointestinal disorders. -
Stable Isotope
Rabeprazole-d3 sodium is a deuterium-labeled form of the second-generation proton pump inhibitor, Rabeprazole sodium, which irreversibly inhibits the gastric H+/K+-ATPase. This compound has been shown to induce apoptosis and acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 value of 0.3 μM. Rabeprazole-d3 sodium is utilized in research involving gastric ulcerations and gastroesophageal reflux disorders. -
Stable Isotope
Pantoprazole-d8 is a deuterium-labeled form of Pantoprazole, a potent proton pump inhibitor (PPI) that targets H+/K+-ATPase with an IC50 of 6.8 μM. This compound exhibits significant anti-secretory and anti-ulcer activities, enhancing gastric pH stability. Research applications include investigating the pharmacokinetics of Pantoprazole and its potential synergistic effects with other chemotherapeutic agents, such as Doxorubicin, in tumor growth modulation. -
Stable Isotope
Rabeprazole-13C,d3 is a deuterated form of Rabeprazole, a second-generation proton pump inhibitor (PPI) that irreversibly inhibits gastric H+/K+-ATPase. This compound is known to induce apoptosis and has been identified as an inhibitor of uridine nucleoside ribohydrolase (UNH) with an IC50 value of 0.3 μM. Rabeprazole-13C,d3 is utilized in research focused on gastric ulcerations and gastroesophageal reflux disease, facilitating the study of drug metabolism and action in biological systems. -
Stable Isotope
Pantoprazole-d3 is a deuterium-labeled form of Pantoprazole, a potent proton pump inhibitor (PPI) that selectively targets the H+/K+-ATPase enzyme, exhibiting an IC50 of 6.8 μM. This compound enhances gastric pH stability and demonstrates significant anti-secretory and anti-ulcer properties. It is utilized in research to study gastric acid secretion mechanisms and to investigate potential synergistic effects with chemotherapeutic agents, such as Doxorubicin, in cancer treatment. -
Stable Isotope
Omeprazole-d3 is a deuterium-labeled variant of Omeprazole, a widely used proton pump inhibitor (PPI) targeting gastric acid secretion. It demonstrates competitive inhibition of CYP2C19 with an inhibition constant (Ki) between 2 to 6 μM, and has been shown to inhibit the growth of both Gram-positive and Gram-negative bacteria. This stable isotope is particularly useful for pharmacokinetic studies, metabolic profiling, and investigations into drug-drug interactions involving Omeprazole. -
Stable Isotope
Omeprazole-13C,d3 is a stable isotope-labeled form of Omeprazole, a proton pump inhibitor (PPI) that targets gastric acid secretion. This compound is utilized in pharmacokinetic studies due to its competitive inhibition of CYP2C19 activity, with an inhibition constant (Ki) ranging from 2 to 6 μM. Additionally, Omeprazole exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria and acts as a potent inhibitor of neutral sphingomyelinase (N-SMase), impacting exosome release. It is a valuable reagent for research in gastrointestinal physiology, drug metabolism, and cellular signaling pathways. -
Stable Isotope
Omeprazole-d3-1 is a deuterium-labeled form of Omeprazole, a proton pump inhibitor (PPI) primarily targeting acid-related gastrointestinal disorders. This compound exhibits competitive inhibition of CYP2C19, with a Ki ranging from 2 to 6 μM, and has demonstrated antimicrobial effects against both Gram-positive and Gram-negative bacteria. Additionally, Omeprazole acts as a potent inhibitor of neutral sphingomyelinase (N-SMase), impacting exosome production in cell studies. This stable isotope is a valuable tool for pharmacokinetic and metabolic research applications. -
Stable Isotope
Omeprazole-d6 is a deuterium-labeled form of Omeprazole, a proton pump inhibitor (PPI) primarily targeting gastric acid secretion. It demonstrates competitive inhibition of CYP2C19 with an inhibition constant (Ki) ranging from 2 to 6 μM, making it a valuable tool in drug metabolism studies. In addition to its role in gastrointestinal health, Omeprazole exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria and serves as a potent inhibitor of neutral sphingomyelinase (N-SMase), thereby impacting exosome production and release. This stable isotope variant is useful for pharmacokinetic studies and tracing in biological research applications. -
Excited-state Intramolecular Proton Transfer Molecules
2-(2′-Hydroxyphenyl)benzimidazole is a well-characterized excited-state intramolecular proton transfer (ESIPT) molecule that demonstrates both normal and tautomer emissions. This compound serves as a valuable fluorescent probe, enabling researchers to explore various biological systems and molecular interactions. Its unique photophysical properties make it an essential tool in studies involving fluorescence spectroscopy and imaging applications. -
Stable Isotope
Lansoprazole-d4 is a deuterium-labeled derivative of Lansoprazole, a proton pump inhibitor that inhibits gastric acid secretion by targeting the H+/K+ ATPase in the gastric parietal cells. The incorporation of deuterium enhances the stability and can facilitate metabolic studies and pharmacokinetic research applications. This stable isotope-labeled compound is valuable for tracing studies, improving analysis of drug metabolism, and understanding the pharmacodynamics of proton pump inhibitors. -
H+, K+-ATPase Inhibitor
Esomeprazole hemistrontium is a potent H+, K+-ATPase inhibitor that functions as an effective proton pump inhibitor. It reduces gastric acid secretion by targeting the H+, K+-ATPase enzyme in parietal cells. This compound is particularly valuable for research applications related to symptomatic gastroesophageal reflux disease. -
H+, K+-ATPase Inhibitor
Esomeprazole (S-Omeprazole) is a potent H+, K+-ATPase inhibitor that functions as an effective proton pump inhibitor. It reduces gastric acid secretion by specifically inhibiting the H+, K+-ATPase enzyme in parietal cells of the stomach lining. This compound is valuable in research related to gastroesophageal reflux disease and studies investigating acid secretion mechanisms. -
Proton Pump Inhibitor
(S)-Lansoprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by inhibiting the proton pump in the stomach lining. This compound demonstrates significant potential for therapeutic applications in acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Additionally, as a neutral sphingomyelinase (N-SMase) inhibitor, it has been investigated for its role in modulating exosome release and may offer insights into neuroprotective research. -
H+, K+-ATPase Inhibitor
Esomeprazole potassium salt is a potent H+, K+-ATPase inhibitor, primarily functioning as a proton pump inhibitor. It effectively reduces gastric acid secretion by targeting the H+, K+-ATPase enzyme in gastric parietal cells. This compound is valuable for research applications focusing on symptomatic gastroesophageal reflux disease and related gastrointestinal disorders. -
Proton Pump Inhibitor
AHR-9294 is a potent inhibitor of the H+ pump enzyme, specifically targeting H, K-ATPase. This compound effectively inhibits gastric acid secretion in vivo, making it valuable for research related to gastrointestinal physiology and the treatment of acid-related disorders. Its mechanism of action supports studies exploring proton pump inhibition and related therapeutic applications. -
H+, K+-ATPase Inhibitor
Esomeprazole magnesium salt is a selective inhibitor of the H+, K+-ATPase enzyme in gastric parietal cells, functioning as an effective proton pump inhibitor. This compound demonstrates significant biological activity by reducing gastric acid secretion. It is primarily utilized in research related to gastroesophageal reflux disease, exploring its therapeutic potential and mechanisms of action in acid-related disorders. -
Proton Pump Inhibitor
S-Pantoprazole sodium trihydrate is a potent proton pump inhibitor that effectively reduces gastric acid secretion. It is primarily utilized in the treatment of conditions associated with excessive gastric acid production, such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its mechanism of action involves the irreversible inhibition of the H+/K+ ATPase enzyme in gastric parietal cells, providing therapeutic benefits in managing acid-related disorders. -
Proton Pump Inhibitor
Lansoprazole sulfide-d4 is a deuterium-labeled form of Lansoprazole sulfide, a bioactive metabolite of the proton pump inhibitor Lansoprazole. This compound exhibits significant activity against Mycobacterium tuberculosis, demonstrating IC50 values of 0.59 μM intracellularly and 0.46 μM in broth. It is a valuable tool for research into anti-tubercular therapies and the pharmacokinetics of proton pump inhibitors. -
Proton Pump Inhibitor
Ilaprazole sodium hydrate is a potent proton pump inhibitor that irreversibly targets H+/K+-ATPase, exhibiting an IC50 value of 6 μM in rabbit parietal cell preparations. This compound is primarily utilized in research related to gastric ulcers, providing insights into gastric acid secretion and its regulation. In addition, Ilaprazole sodium hydrate demonstrates inhibitory activity against TOPK (T-lymphokine-activated killer cell-originated protein kinase), making it a valuable tool for studies on cellular signaling pathways and cancer research. -
Overoxidized By-product of Lansoprazole
Lansoprazole N-oxide is the overoxidized by-product derived from the synthesis of the proton pump inhibitor Lansoprazole. This compound is of interest for studies related to gastrointestinal disorders, including duodenal and gastric ulcers, reflux esophagitis, and Zollinger–Ellison syndrome. Researchers may utilize Lansoprazole N-oxide to deepen the understanding of proton pump inhibition and its implications in these conditions.
